Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  NeoStem Inc    NBS

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

NeoStem Inc : NeoStem Announces Closing of Public Offering of Common Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 03:46pm CEST

NeoStem Announces Closing of Public Offering of Common Stock May 3 2013

New York, May 3, 2013 -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the closing of a previously announced underwritten public offering of 23,000,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 3,000,000 shares, offered at a price to the public of $0.50 per share. The gross proceeds to the Company were $11,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Aegis Capital Corp. acted as sole book-running manager of the offering.

This offering is being made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC), and which became effective on October 3, 2012. Electronic copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the SEC's website at http://www.sec.gov or from Aegis Capital Corp, 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company's securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEOSTEM INC
09/20 ADAPTIMMUNE THERAPEUTICS : Announces Strategic Manufacturing Agreement with PCT ..
09/19 CALADRIUS BIOSCIENCES : Subsidiary, PCT, Announces Five-Year Strategic Manufactu..
09/16 CALADRIUS BIOSCIENCES : Enters Into Agreements To Raise $25 Million in Common Eq..
09/15 CALADRIUS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Unregi..
09/15 Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in Co..
09/08 Caladrius Biosciences to Present at Upcoming September Conferences
09/08 CALADRIUS BIOSCIENCES : Completes Enrollment of First Patient Cohort in Phase 2 ..
09/06 Caladrius Biosciences Completes Enrollment of First Patient Cohort in Phase 2..
08/09 CALADRIUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Cha..
08/09 CALADRIUS BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
More news
Sector news : Biotechnology & Medical Research - NEC
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials ($)
Sales 2016 30,6 M
EBIT 2016 -36,8 M
Net income 2016 -38,5 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0,90x
Capi. / Sales 2017 0,77x
Capitalization 27,6 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 14,0 $
Spread / Average Target 200%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David J. Mazzo Chief Executive Officer & Director
Steven S. Myers Chairman
Joseph Talamo Chief Financial Officer & Senior Vice President
Douglas W. Losordo Chief Medical Officer & SVP-Regulatory Affairs
Robert A. Preti Director, Chief Technical Officer & Senior VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOSTEM INC27
INCYTE CORPORATION-14.06%16 687
CELLTRION, INC.--.--%11 639
LONZA GROUP AG12.32%9 948
QUINTILES TRANSNATIONA..15.89%9 402
SEATTLE GENETICS, INC.23.28%7 828
More Results